Abstract:

Aim: Urinary tract infections are the infections for which antibiotics are most frequently prescribed to outpatients. The purpose of this study is to evaluate the ten-year change in antibiotic resistance profiles of microorganisms grown in urine cultures. Material and Method: The results of urine cultures that were sent to the Microbiology Laboratory between 01.01.2013 and 31.12.2022 were evaluated retrospectively. Identification and antimicrobial susceptibility of microorganisms were performed with the BD Phoenix 100 (Becton Dickinson, Maryland, USA) device between 2015-2016, and with the VITEK-2 compact system (BioMérieux, France) between 2013-2014, 2017-2022. While the antibiotic susceptibility results of the isolates were interpreted using the clinical breakpoints defined by the Clinical Laboratory and Standards Institute (CLSI) between 2013 and 2015, they were evaluated according to the EUCAST (European Committee for Antimicrobial Susceptibility Testing) criteria after 2015. Results: The most common microorganism is Eschericha coli (E. coli) (4898) with 49%, while the second most common agent is Klebsiella spp with 13.8%. (1380) were gram-negative microorganisms. While the most sensitive antibiotics were carbapenem and aminoglycoside groups in E. coli and Klebsiella spp, the resistance to ampicillin, ciprofloxacin and cephalosporins in E. coli was over 60%, while this rate was around 80% in Klebsiella spp. In our study, resistance rates of PIP-TZP, ceftazidime, carbapenems, aminoglycosides and quinolones were higher against Acinetobacter spp than Pseudomonas spp. In general, resistance to Acinetobacter spp. and Klebsiella spp, and there was a tendency for the resistance rates of all microorganisms to increase over the years. Conclusion: Creating more detailed cumulative antibiogram reports, sharing these reports with relevant clinics within specified periods, establishing antimicrobial management teams that will work in harmony with infection control committees in hospitals, structuring a nationwide surveillance program; It will contribute to the determination of empirical treatment, prevention of the development of antimicrobial resistance and control of hospital-acquired infections.

Keywords: